The European Association of Nuclear Medicine (EANM) Congress is one of the most important annual gatherings in the field of nuclear medicine, molecular imaging, and radiopharmaceutical development. Each year, the event brings together leading experts, researchers, and companies to exchange knowledge, present scientific advances, and discuss the future of patient care.

We are thrilled to share that Medi-Radiopharma will be exhibiting for the very first time at CPHI 2025! This global event is the ultimate meeting point for the pharmaceutical industry, bringing together innovators, manufacturers, service providers, and partners from across the world.

The XXIII. MONT Congress (Hungarian Society of Nuclear Medicine – Hevesy György Hungarian Society of Nuclear Medicine) is one of the most important professional events for the Hungarian nuclear medicine and medical community.

2025 marks a major milestone for the Medi-Radiopharma family – we're celebrating 30 years of innovation in nuclear medicine and preparing to open our brand-new manufacturing facility following FDA and EMA certification by the end of the year!

During June 12-15, 2024 we had the pleasure of attending the India Health Conference in New Delhi.

Our MRP team was present with a large delegation & booth at the 37th Annual Congress of the European Association of Nuclear Medicine held in Hamburg, Germany.

Join the team of exceptional professionals and contribute to positive patient outcomes around the world. Medi-Radiopharma is increasing its production capacity in Hungary by building a new plant in order to meet market demands. The expansion consists of two phases, by the end of which the capacity of 3.2 million vials/year will be reached, which is sufficient to cover the entire European and Global market.

Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving factors behind the company’s success and his long-term vision of for the company.